Clinical drug interactions with medicinal herbs

Evidence-Based Integrative Medicine

Volumn 2, Issue 4, 2005, Pages 207-228

  Johne, Andreas ^a   Roots, Ivar ^a  

^a CHARITÉ UNIVERSITÄTSMEDIZIN BERLIN   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

ACETYLSALICYLIC ACID; ANTARES; BIO BILOBA; CAFFEINE; CARBAMAZEPINE; CHLORPROMAZINE; CHLORZOXAZONE; CRATAEGUS EXTRACT; CURBICIN; DEBRISOQUINE; DEXTROMETHORPHAN; ECHINACEA EXTRACT; EFAVITE; ENOTHERA BIENNIS EXTRACT; ERGOTAMINE; FLUPHENAZINE; GARLIC EXTRACT; GARLIPURE; GINGIUM; GINKGO BILOBA EXTRACT; GINKGOLON 24; GLIBENCLAMIDE; HARPAGOPHYTUM EXTRACT; HERBACEOUS AGENT; KAVA EXTRACT; KAVASPORAL; LISINOPRIL; MIDAZOLAM; PARACETAMOL; PEPPERMINT; PRIMROSE OIL; PROSTACTIVE; REMEMBRANCE; RITONAVIR; SABAL EXTRACT; SAQUINAVIR; SILYBON; SILYBUM MARIANUM EXTRACT; SILYMARIN; THISILYN; TOLBUTAMIDE; UNCLASSIFIED DRUG; UNINDEXED DRUG; VALEPOTRIATE; VALERIAN;

ALLERGIC REACTION; ANXIETY; AREA UNDER THE CURVE; ARTHROPATHY; ATOPIC DERMATITIS; BLEEDING; BRAIN HEMORRHAGE; CARDIOVASCULAR DISEASE; CLINICAL TRIAL; COGNITIVE DEFECT; COMA; DATA BASE; DELIRIUM; DEMENTIA; DISORIENTATION; DOSE RESPONSE; DRUG DELIVERY SYSTEM; DRUG EFFECT; DRUG TOLERABILITY; DYSPEPSIA; EPILEPTIC STATE; EVENING PRIMROSE; GASTROINTESTINAL SYMPTOM; GRAND MAL SEIZURE; HEADACHE; HERB DRUG INTERACTION; HUMAN; HYDRASTIS; HYDRASTIS CANADENSIS EXTRACT; HYPHEMA; INFECTION; INTERMITTENT CLAUDICATION; INTERNET; LETHARGY; LIVER DISEASE; LIVER TOXICITY; LOW BACK PAIN; MASTALGIA; MAXIMUM ALLOWABLE CONCENTRATION; MENSTRUATION DISORDER; META ANALYSIS; NAUSEA AND VOMITING; NONHUMAN; ORTHOSTATIC HYPERTENSION; PROSTATE HYPERTROPHY; RETROBULBAR HEMORRHAGE; REVIEW; RHEUMATOID ARTHRITIS; SABAL; SCHIZOPHRENIA; SUBARACHNOID HEMORRHAGE; SUBDURAL HEMATOMA; SYSTEMATIC REVIEW; TONIC CLONIC SEIZURE; UNSPECIFIED SIDE EFFECT; UPPER RESPIRATORY TRACT INFECTION;

EID: 33646735774     PISSN: 11762330     EISSN: 11762330     Source Type: Journal    
DOI: 10.2165/01197065-200502040-00004     Document Type: Review

References (267)

1. Pirmohamed M, James S, Meakin S, et al. Adverse drug reactions as cause of admission to hospital: prospective analysis of 18 820 patients. BMJ 2004; 329: 15-9
2. Lazarou J, Pomeranz BH, Corey PN. Incidence of adverse drug reactions in hospitalized patients: a meta-analysis of prospective studies. JAMA 1998; 279: 1200-5
3. Williamson EM. Synergy and other interactions in phytomedicines. Phytomedicine 2001; 8: 401-9
4. Johne A, Brockmöller J, Bauer S, et al. Pharmacokinetic interaction of digoxin with an herbal extract from St John's wort (Hypericum perforatum). Clin Pharmacol Ther 1999; 66: 338-45
5. Piscitelli SC, Burstein AH, Chaitt D, et al. Indinavir concentrations and St John's wort. Lancet 2000; 355: 547-8
6. Johne A, Schmider J, Brockmöller J, et al. Lowered plasma levels of amitriptyline and its metabolites upon co-medication with an extract from St. John's wort (Hypericum perforatum). J Clin Psychopharmacol 2002; 22: 46-54
7. Wentworth JM, Agostini M, Love J, et al. St John's wort, a herbal antidepressant, activates the steroid X receptor. J Endocrinol 2000; 166: R11-6
8. Mai I, Bauer S, Perloff ES, et al. Hyperforin content determines the magnitude of the Saint John's wort-cyclosporine drug interaction. Clin Pharmacol Ther 2004; 76: 330-40
9. Henderson L, Yue QY, Bergquist C, et al. St John's wort (Hypericum perforatum): drug interactions and clinical outcomes. Br J Clin Pharmacol 2002; 54: 349-56
10. Johne A, Roots I. Adverse drug effects and interactions: what is the current thinking about the use of St. John's wort? [in German]. Pharm Unserer Zeit 2003; 32: 242-6
11. Mannel M. Drug interactions with St John's wort: mechanisms and clinical implications. Drug Saf 2004; 27: 773-97
12. Miller LG. Herbal medicinals: selected clinical considerations focusing on known or potential drug-herb interactions. Arch Intern Med 1998; 158: 2200-11
13. Fugh-Berman A. Herb-drug interactions. Lancet 2000; 355: 134-8
14. Ernst E. Interactions between synthetic and herbal medicinal products. Part 2: a systemic review of the direct evidence. Perfusion 2000; 13: 60-70
15. Ang-Lee MK, Moss J, Yuan CS. Herbal medicines and perioperative care. JAMA 2001; 286: 208-16
16. Izzo AA, Ernst E. Interactions between herbal medicines and prescribed drugs: a systematic review. Drugs 2001; 61: 2163-75
17. Bhattaram VA, Graefe U, Kohlert C, et al. Pharmacokinetics and bioavailability of herbal medicinal products. Phytomedicine 2002; 9: 1-33
18. Ioannides C. Pharmacokinetic interactions between herbal remedies and medicinal drugs. Xenobiotica 2002; 32: 451-78
19. Zhou S, Gao Y, Jiang W, et al. Interactions of herbs with cytochrome P450. Drug Metab Rev 2003; 35: 35-98
20. Fugh-Berman A, Ernst E. Herb-drug interactions: review and assessment of report reliability. Br J Clin Pharmacol 2001; 52: 587-95
21. Shaw D, Leon C, Kolev S, et al. Traditional remedies and food supplements: a 5-year toxicological study (1991-1995). Drug Saf 1997; 17: 342-56
22. Vaddadi KS. The use of gamma-linolenic acid and linoleic acid to differentiate between temporal lobe epilepsy and schizophrenia. Prostaglandins Med 1981; 6: 375-9
23. Holman CP, Bell AFJ. A trial of evening primrose oil in the treatment of chronic schizophrenia. J Orthomolecular Psychiatry 1983; 12: 302-4
24. Aslam M, Stockley IH. Interaction between curry ingredient (karela) and drug (chlorpropamide). Lancet 1979; I: 607
25. Sunter WH. Warfarin and garlic [letter]. Pharm J 1991; 246: 722
26. Pathak A, Leger P, Bagheri H, et al. Garlic interaction with fluindione: a case report. Therapie 2003; 58: 380-1
27. Laroche M, Choudri S, Gallicano K, et al. Severe gastrointestinal toxicity with concomitant ingestion of ritonavir and garlic [abstract]. Can J Infect Dis 1998; 9 Suppl. A: 471P
28. Haase G, Riethling AK, Drewelow B. Serious ADR associated with Ginkgo biloba [abstract]. Eur J Clin Pharmacol 2002; 58: S95
29. Rowin J, Lewis SL. Spontaneous bilateral subdural hematomas associated with chronic Ginkgo biloba ingestion. Neurology 1996; 46: 1775-6
30. Hoffman T. Ginko, Vioxx and excessive bleeding: possible drug-herb interactions: case report. Hawaii Med J 2001; 60: 290
31. Rosenblatt M, Mindel J. Spontaneous hyphema associated with ingestion of Ginkgo biloba extract. N Engl J Med 1997; 336: 1108
32. Hauser D, Gayowski T, Singh N. Bleeding complications precipitated by unrecognized Gingko biloba use after liver transplantation. Transpl Int 2002; 15: 377-9
33. Meisel C, Johne A, Roots I. Fatal intracerebral mass bleeding associated with Ginkgo biloba and ibuprofen. Atherosclerosis 2003; 167: 367
34. Matthews Jr MK. Association of Ginkgo biloba with intracerebral hemorrhage. Neurology 1998; 50: 1933-4
35. Galluzzi S, Zanetti O, Binetti G, et al. Coma in a patient with Alzheimer's disease taking low dose trazodone and gingko biloba. J Neurol Neurosurg Psychiatry 2000; 68: 679-80
36. Granger AS. Ginkgo biloba precipitating epileptic seizures. Age Ageing 2001; 30: 523-5
37. Schelosky L, Raffauf C, Jendroska K, et al. Kava and dopamine antagonism. J Neurol Neurosurg Psychiatry 1995; 58: 639-40
38. Ballesteros S, Adan S, Ramon MF, et al. Severe adverse effect associated with kava kava [abstract]. J Toxicol Clin Toxicol 2001; 39: 312
39. Almeida JC, Grimsley EW. Coma from the health food store: interaction between kava and alprazolam. Ann Intern Med 1996; 125: 940-1
40. Yue QY, Jansson K. Herbal drug curbicin and anticoagulant effect with and without warfarin: possibly related to the vitamin E component. J Am Geriatr Soc 2001; 49: 838
41. Khawaja IS, Marotta RF, Lippmann S. Herbal medicines as a factor in delirium. Psychiatr Serv 1999; 50: 969-70
42. Yager J, Siegfreid SL, DiMatteo TL. Use of alternative remedies by psychiatric patients: illustrative vignettes and a discussion of the issues. Am J Psychiatry 1999; 156: 1432-8
43. Gorski JC, Huang SM, Pinto A, et al. The effect of echinacea (Echinacea purpurea root) on cytochrome P450 activity in vivo. Clin Pharmacol Ther 2004; 75: 89-100
44. Gurley BJ, Gardner SF, Hubbard MA, et al. Assessment of botanical supplementation on human cytochrome P450 phenotype: citrus aurantium, echinacea, milk thistle, saw palmetto. Clin Pharmacol Ther 2004; 76: 428-40
45. Gallicano K, Foster B, Choudhri S. Effect of short-term administration of garlic supplements on single-dose ritonavir pharmacokinetics in healthy volunteers. Br J Clin Pharmacol 2003; 55: 199-202
46. Piscitelli SC, Burstein AH, Welden N, et al. The effect of garlic supplements on the pharmacokinetics of saquinavir. Clin Infect Dis 2002; 34: 234-8
47. Jacek H, Rentsch KM, Steinert HC, et al. No effect of garlic extract on saquinavir kinetics and hepatic CYP3A4 function measured by the erythromycin breath test [abstract]. Pharmacol Ther 2004; 75: P80
48. Markowitz JS, Devane CL, Chavin KD, et al. Effects of garlic (Allium sativum L.) supplementation on cytochrome P450 2D6 and 3A4 activity in healthy volunteers. Clin Pharmacol Ther 2003; 74: 170-7
49. Gurley BJ, Gardner SF, Hubbard MA, et al. Cytochrome P450 phenotypic ratios for predicting herb-drug interactions in humans. Clin Pharmacol Ther 2002; 72: 276-87
50. Loizou GD, Cocker J. The effects of alcohol and diallyl sulphide on CYP2E1 activity in humans: a phenotyping study using chlorzoxazone. Hum Exp Toxicol 2001; 20: 321-7
51. Gwilt PR, Lear CL, Tempero MA, et al. The effect of garlic extract on human metabolism of acetaminophen. Cancer Epidemiol Biomarkers Prev 1994; 3: 155-60
52. Tebonin® Fachinformation. Karlsruhe, Germany: Dr Willmar Schwabe GmbH & Co., 2004. (Data on file)
53. Engelsen J, Nielsen JD, Winther K. Effect of coenzyme Q10 and Ginkgo biloba on warfarin dosage in stable, long-term warfarin treated outpatients: a randomised, double blind, placebo- crossover trial. Thromb Haemost 2002; 87: 1075-6
54. Yasui-Furukori N, Furukori H, Kaneda A, et al. The effects of Ginkgo biloba extracts on the pharmacokinetics and pharmacodynamics of donepezil. J Clin Pharmacol 2004; 44: 538-42
55. Duche JC, Barre J, Guinot P, et al. Effect of Ginkgo biloba extract on microsomal enzyme induction. Int J Clin Pharmacol Res 1989; 9: 165-8
56. Smith M, Lin KM, Zheng YP. An open trial of nifedipine-herb interactions: nifedipine with St. John's wort, ginseng or Ginkgo biloba. Clin Pharmacol Ther 2001; 69: P86
57. Sun H, Zuo Z, Yin OQ, et al. A "high-throughput" cocktail method for screening the effect of herbal product on liver isozyme activities: experience with Ginkgo biloba. Clin Pharmacol Ther 2002; 71: P100
58. Mauro VF, Mauro LS, Kleshinski JF, et al. Impact of Ginkgo biloba on the pharmacokinetics of digoxin. Am J Ther 2003; 10: 247-51
59. Markowitz JS, Donovan JL, Devane CL, et al. Multiple-dose administration of Ginkgo biloba did not affect cytochrome P-450 2D6 or 3A4 activity in normal volunteers. J Clin Psychopharmacol 2003; 23: 576-81
60. Yin OQ, Tomlinson B, Waye MM, et al. Pharmacogenetics and herb-drug interactions: experience with Ginkgo biloba and omeprazole. Pharmacogenetics 2004; 14: 841-50
61. Yoshioka M, Ohnishi N, Koishi T, et al. Studies on interactions between functional foods or dietary supplements and medicines: IV. Effects of Ginkgo biloba leaf extract on the pharmacokinetics and pharmacodynamics of nifedipine in healthy volunteers. Biol Pharm Bull 2004; 27: 2006-9
62. Uchida S, Yamada H, Li XD, et al. Effects of Ginkgo biloba extract on pharmacokinetics and pharmacodynamics of tolbutamide and midazolam [abstract]. Clin Exp Pharmacol Physiol 2004; 31: A219-20
63. Greenblatt DJ, von Moltke LL, Perloff ES, et al. Effect of ginkgo on CYP2C9: in vitro and in vivo studies. Clin Pharmacol Ther 2005; 77: P48
64. Sandhu RS, Prescilla RP, Simonelli TM, et al. Influence of goldenseal root on the pharmacokinetics of indinavir. J Clin Pharmacol 2003; 43: 1283-8
65. Gurley BJ, Gardner SF, Williams DK, et al. Effect of goldenseal, black cohosh, kava kava, and valerian on human cytochrome P450 1A2, 2D6, 2E1, and 3A4 phenotypes [abstract]. Clin Pharmacol Ther 2005; 77: P36
66. Tankanow R, Tamer HR, Streetman DS, et al. Interaction study between digoxin and a preparation of hawthorn (Crataegus oxyacantha). J Clin Pharmacol 2003; 43: 637-42
67. Russmann S, Barguil Y, Wenk M, et al. Traditional aqueous kava extracts inhibit CYP4501A2 in humans [abstract]. Clin Pharmacol Ther 2004; 75: P83
68. Herberg KW. Safety-related performance after intake of kava-extract, bromazepam and their combination [in German]. Z Allgemeinmed 1996; 72: 973-7
69. Foo H, Lemon J. Acute effects of kava, alone or in combination with alcohol, on subjective measures of impairment and intoxication and on cognitive performance. Drug Alcohol Rev 1997; 16: 147-55
70. Herberg KW. Effect of kava-special extract WS 1490 combined with ethyl alcohol on safety-relevant performance parameters [in German]. Blutalkohol 1993; 30: 96-105
71. Leber HW, Knauff S. Influence of silymarin on drug metabolizing enzymes in rat and man. Arzneimittelforschung 1976; 26: 1603-5
72. Piscitelli SC, Formentini E, Burstein AH, et al. Effect of milk thistle on the pharmacokinetics of indinavir in healthy volunteers. Pharmacotherapy 2002; 22: 551-6
73. DiCenzo R, Shelton M, Jordan K, et al. Coadministration of milk thistle and indinavir in healthy subjects. Pharmacotherapy 2003; 23: 866-70
74. Mills E, Wilson K, Clarke M, et al. Milk thistle and indinavir: a randomized controlled pharmacokinetics study and meta-analysis. Eur J Clin Pharmacol 2005; 61 (1): 1-7
75. Gurley BJ, Hubbard MA, Barone G, et al. Assessment of milk thistle and black cohosh supplementation on digoxin pharmacokinetics [abstract]. Clin Pharmacol Ther 2005; 77: P49
76. Rajnarayana K, Reddy MS, Vidyasagar J, et al. Study on the influence of silymarin pretreatment on metabolism and disposition of metronidazole. Arzneimittelforschung 2004; 54: 109-13
77. Dresser GK, Wacher V, Wong S, et al. Evaluation of peppermint oil and ascorbyl palmitate as inhibitors of cytochrome P4503A4 activity in vitro and in vivo. Clin Pharmacol Ther 2002; 72: 247-55
78. Dresser GK, Wacher V, Ramtoola Z, et al. Peppermint oil increases the oral bioavailability of felodipine and simvastatin [abstract]. Clin Pharmacol Ther 2002; 71: P67
79. Markowitz JS, Donovan JL, Devane CL, et al. Multiple doses of saw palmetto (Serenoa repens) did not alter cytochrome P450 2D6 and 3A4 activity in normal volunteers. Clin Pharmacol Ther 2003; 74: 536-42
80. Mayer B, Springer E. Psychoexperimental studies on the effect of a valepotriate combination as well as the combined effects of valtratum and alcohol [in German]. Arzneimittelforschung 1974; 24: 2066-70
81. Kohnen R, Oswald WD. The effects of valerian, propranolol, and their combination on activation, performance, and mood of healthy volunteers under social stress conditions. Pharmacopsychiatry 1988; 21: 447-8
82. Donovan JL, DeVane CL, Chavin KD, et al. Multiple night-time doses of valerian (Valeriana officinalis) had minimal effects on CYP3A4 activity and no effect on CYP2D6 activity in healthy volunteers. Drug Metab Dispos 2004; 32: 1333-6
83. Gagnier JJ, Chrubasik S, Manheimer E. Harpagophytum procumbens for osteoarthritis and low back pain: a systematic review. BMC Complement Altern Med 2004; 4: 13
84. Wegener T. Die Teufelskralle (Harpagophytum procumbens DC.) in der Therapie rheumatischer Erkrankungen. Z Phytother 1998; 19: 284-94
85. Loew D, Mollerfeld J, Schrodter A, et al. Investigations on the pharmacokinetic properties of Harpagophytum extracts and their effects on eicosanoid biosynthesis in vitro and ex vivo. Clin Pharmacol Ther 2001; 69: 356-64
86. Moussard C, Alber D, Toubin MM, et al. A drug used in traditional medicine, Harpagophytum procumbens: no evidence for NSAID-like effect on whole blood eicosanoid production in human. Prostaglandins Leukot Essent Fatty Acids 1992; 46: 283-6
87. Borchers AT, Keen CL, Stern JS, et al. Inflammation and Native American medicine: the role of botanicals. Am J Clin Nutr 2000; 72: 339-47
88. Bauer R. Echinacea drugs: effects and active ingredients [in German]. Z Arztl Fortbild (Jena) 1996; 90: 111-5
89. Melchart D, Linde K, Fischer P, et al. Echinacea for preventing and treating the common cold. Cochrane Database Syst Rev 2000; (2): CD000530
90. Barrett B. Medicinal properties of Echinacea: a critical review. Phytomedicine 2003; 10: 66-86
91. Blumenthal M. The complete German commission E monographs, therapeutic guide to herbal medicines. Austin (TX): American Botanical Council, 1998
92. Osowski S, Rostock M, Bartsch HH, et al. Pharmaceutical comparability of different therapeutic Echinacea preperations [in German]. Forsch Komplementarmed Klass Naturheilkd 2000; 7: 294-300
93. Perry NB, Burgess EJ, Glennie VL. Echinacea standardization: analytical methods for phenolic compounds and typical levels in medicinal species. J Agric Food Chem 2001; 49: 1702-6
94. Gilroy CM, Steiner JF, Byers T, et al. Echinacea and truth in labeling. Arch Intern Med 2003; 163: 699-704
95. Mullins RJ, Heddle R. Adverse reactions associated with echinacea: the Australian experience. Ann Allergy Asthma Immunol 2002; 88: 42-51
96. Budzinski JW, Foster BC, Vandenhoek S, et al. An in vitro evaluation of human cytochrome P450 3A4 inhibition by selected commercial herbal extracts and tinctures. Phytomedicine 2000; 7: 273-82
97. Strandell J, Neil A, Carlin G. An approach to the in vitro evaluation of potential for cytochrome P450 enzyme inhibition from herbals and other natural remedies. Phytomedicine 2004; 11: 98-104
98. Dresser GK, McDonald W, Kim RB, et al. Evaluation of herbal products as potential inhibitors of MDR1 [abstract]. Clin Pharmacol Ther 2004; 75: P79
99. Manku MS, Horrobin DF, Morse NL, et al. Essential fatty acids in the plasma phospholipids of patients with atopic eczema. Br J Dermatol 1984; 110: 643-8
100. Horrobin DF, Manku MS. Premenstrual syndrome and premenstrual breast pain (cyclical mastalgia): disorders of essential fatty acid (EFA) metabolism. Prostaglandins Leukot Essent Fatty Acids 1989; 37: 255-61
101. Morse PF, Horrobin DF, Manku MS, et al. Meta-analysis of placebo-controlled studies of the efficacy of Epogam in the treatment of atopic eczema: relationship between plasma essential fatty acid changes and clinical response. Br J Dermatol 1989; 121: 75-90
102. Little C, Parsons T. Herbal therapy for treating rheumatoid arthritis. Cochrane Database Syst Rev 2001; (1): CD002948
103. Hardy ML. Herbs of special interest to women. J Am Pharm Assoc (Wash) 2000; 40: 234-42
104. Martens-Lobenhoffer J, Meyer FP. Pharmacokinetic data of gamma-linolenic acid in healthy volunteers after the administration of evening primrose oil (Epogam). Int J Clin Pharmacol Ther 1998; 36: 363-6
105. Joy CB, Mumby-Croft R, Joy LA. Polyunsaturated fatty acid supplementation for schizophrenia. Cochrane Database Syst Rev 2003; (2): CD001257
106. Lawson LD, Wang ZJ, Hughes BG. Identification and HPLC quantitation of the sulfides and dialk(en)yl thiosulfinates in commercial garlic products. Planta Med 1991; 57: 363-70
107. Amagase H, Petesch BL, Matsuura H, et al. Intake of garlic and its bioactive components. J Nutr 2001; 131: 955S-62S
108. Lawson LD, Wang ZJ. Low allicin release from garlic supplements: a major problem due to the sensitivities of alliinase activity. J Agric Food Chem 2001; 49: 2592-9
109. Schulz V, Hänsel R, Tyler VE. Rational phytotherapy: a physicians' guide to herbal medicine. 4th ed. Berlin: Springer Verlag, 2001
110. Ackermann RT, Mulrow CD, Ramirez G, et al. Garlic shows promise for improving some cardiovascular risk factors. Arch Intern Med 2001; 161: 813-24
111. Kiesewetter H, Jung F, Pindur G, et al. Effect of garlic on thrombocyte aggregation, microcirculation, and other risk factors. Int J Clin Pharmacol Ther Toxicol 1991; 29: 151-5
112. Li G, Shi Z, Jia H, et al. A clinical investigation on garlicin injectio for treatment of unstable angina pectoris and its actions on plasma endothelin and blood sugar levels. J Tradit Chin Med 2000; 20: 243-6
113. Jain AK, Vargas R, Gotzkowsky S, et al. Can garlic reduce levels of serum lipids? A controlled clinical study. Am J Med 1993; 94: 632-5
114. Bordia A, Verma SK, Srivastava KC. Effect of garlic (Allium sativum) on blood lipids, blood sugar, fibrinogen and fibrinolytic activity in patients with coronary artery disease. Prostaglandins Leukot Essent Fatty Acids 1998; 58: 257-63
115. Sitprija S, Plengvidhya C, Kangkaya V, et al. Garlic and diabetes mellitus phase II clinical trial. J Med Assoc Thai 1987; 70 Suppl. 2: 223-7
116. Mansell P, Reckless JP, Lloyd J. The effect of dried garlic powder tablets on serum lipids in non-insulin dependent diabetic patients. Eur J Clin Res 1996; 8: 25-6
117. Grover JK, Yadav S, Vats V. Medicinal plants of India with anti-diabetic potential. J Ethnopharmacol 2002; 81: 81-100
118. Basch E, Gabardi S, Ulbricht C. Bitter melon (Momordica charantia): a review of efficacy and safety. Am J Health Syst Pharm 2003; 60: 356-9
119. Ali M, Thomson M, Afzal M. Garlic and onions: their effect on eicosanoid metabolism and its clinical relevance. Prostaglandins Leukot Essent Fatty Acids 2000; 62: 55-73
120. Rahman K, Billington D. Dietary supplementation with aged garlic extract inhibits ADP-induced platelet aggregation in humans. J Nutr 2000; 130: 2662-5
121. Steiner M, Lin RS. Changes in platelet function and susceptibility of lipoproteins to oxidation associated with administration of aged garlic extract. J Cardiovasc Pharmacol 1998; 31: 904-8
122. Bordia A, Verma SK, Srivastava KC. Effect of garlic on platelet aggregation in humans: a study in healthy subjects and patients with coronary artery disease. Prostaglandins Leukot Essent Fatty Acids 1996; 55: 201-5
123. Kiesewetter H, Jung F, Jung EM, et al. Effect of garlic on platelet aggregation in patients with increased risk of juvenile ischaemic attack. Eur J Clin Pharmacol 1993; 45: 333-6
124. Legnani C, Frascaro M, Guazzaloca G, et al. Effects of a dried garlic preparation on fibrinolysis and platelet aggregation in healthy subjects. Arzneimittelforschung 1993; 43: 119-22
125. Jain RC. Effect of garlic on serum lipids, coagulability and fibrinolytic activity of blood. Am J Clin Nutr 1977; 30: 1380-1
126. Rose KD, Croissant PD, Parliament CF, et al. Spontaneous spinal epidural hematoma with associated platelet dysfunction from excessive garlic ingestion: a case report. Neurosurgery 1990; 26: 880-2
127. German K, Kumar U, Blackford HN. Garlic and the risk of TURP bleeding. Br J Urol 1995; 76: 518
128. Burnham BE. Garlic as a possible risk for postoperative bleeding. Plast Reconstr Surg 1995; 95: 213
129. Harenberg J, Giese C, Zimmermann R. Effect of dried garlic on blood coagulation, fibrinolysis, platelet aggregation and serum cholesterol levels in patients with hyperlipoproteinemia. Atherosclerosis 1988; 74: 247-9
130. Luley C, Lehmann-Leo W, Moller B, et al. Lack of efficacy of dried garlic in patients with hyperlipoproteinemia. Arzneimittelforschung 1986; 36: 766-8
131. Siess MH, Le Bon AM, Canivenc-Lavier MC, et al. Modification of hepatic drug-metabolizing enzymes in rats treated with alkyl sulfides. Cancer Lett 1997; 120: 195-201
132. Sheen LY, Chen HW, Kung YL, et al. Effects of garlic oil and its organosulfur compounds on the activities of hepatic drug-metabolizing and antioxidant enzymes in rats fed high- and low-fat diets. Nutr Cancer 1999; 35: 160-6
133. Guyonnet D, Siess MH, Le Bon AM, et al. Modulation of phase II enzymes by organosulfur compounds from allium vegetables in rat tissues. Toxicol Appl Pharmacol 1999; 154: 50-8
134. Fujita K, Kamataki T. Screening of organosulfur compounds as inhibitors of human CYP2A6. Drug Metab Dispos 2001; 29: 983-9
135. Wu CC, Sheen LY, Chen HW, et al. Differential effects of garlic oil and its three major organosulfur components on the hepatic detoxification system in rats. J Agric Food Chem 2002; 50: 378-83
136. Foster BC, Foster MS, Vandenhoek S, et al. An in vitro evaluation of human cytochrome P450 3A4 and P-glycoprotein inhibition by garlic. J Pharm Pharm Sci 2001; 4: 176-84
137. Arora A, Seth K, Shukla Y. Reversal of P-glycoprotein-mediated multidrug resistance by diallyl sulfide in K562 leukemic cells and in mouse liver. Carcinogenesis 2004; 25: 941-9
138. Yang CS, Chhabra SK, Hong JY, et al. Mechanisms of inhibition of chemical toxicity and carcinogenesis by diallyl sulfide (DAS) and related compounds from garlic. J Nutr 2001; 131: 1041S-5S
139. DeFeudis FV, Drieu K. Ginkgo biloba extract (EGb 761) and CNS functions: basic studies and clinical applications. Curr Drug Targets 2000; 1: 25-58
140. Blumenthal M. Herbs continue slide in mainstream market: sales down 14 percent. HerbalGram 2003; 58: 71
141. Birks J, Grimley EJ, Van Dongen M. Ginkgo biloba for cognitive impairment and dementia. Cochrane Database Syst Rev 2002; (4): CD003120
142. Pittler MH, Ernst E. Ginkgo biloba extract for the treatment of intermittent claudication: a meta-analysis of randomized trials. Am J Med 2000; 108: 276-81
143. Jaggy H, Koch E. Chemistry and biology of alkylphenols from Ginkgo biloba L. Pharmazie 1997; 52: 735-8
144. Kressmann S, Muller WE, Blume HH. Pharmaceutical quality of different Ginkgo biloba brands. J Pharm Pharmacol 2002; 54: 661-9
145. Maclennan KM, Darlington CL, Smith PF. The CNS effects of Ginkgo biloba extracts and ginkgolide B. Prog Neurobiol 2002; 67: 235-57
146. Chung KF, Dent G, McCusker M, et al. Effect of a ginkgolide mixture (BN 52063) in antagonising skin and platelet responses to platelet activating factor in man. Lancet 1987; I: 248-51
147. Gilbert GJ. Ginkgo biloba [letter]. Neurology 1997; 48: 1137
148. Vale S. Subarachnoid haemorrhage associated with Ginkgo biloba. Lancet 1998; 352: 36
149. Benjamin J, Muir T, Briggs K, et al. A case of cerebral haemorrhage: can Ginkgo biloba be implicated? Postgrad Med J 2001; 77: 112-3
150. Fessenden JM, Wittenborn W, Clarke L. Gingko biloba: a case report of herbal medicine and bleeding postoperatively from a laparoscopic cholecystectomy. Am Surg 2001; 67: 33-5
151. Schneider C, Bord C, Misse P, et al. Spontaneous hyphema caused by Ginkgo biloba extract [in French]. J Fr Ophtalmol 2002; 25: 731-2
152. Fong KC, Kinnear PE. Retrobulbar haemorrhage associated with chronic Gingko biloba ingestion. Postgrad Med J 2003; 79: 531-2
153. Israeli A, Matzner Y, Or R, et al. Glibenclamide causing thrombocytopenia and bleeding tendency: case reports and a review of the literature. Klin Wochenschr 1988; 66: 223-4
154. Weaver AL. Rofecoxib: clinical pharmacology and clinical experience. Clin Ther 2001; 23: 1323-38
155. Kim YS, Pyo MK, Park KM, et al. Antiplatelet and antithrombotic effects of a combination of ticlopidine and Ginkgo biloba ext (EGb 761). Thromb Res 1998; 91: 33-8
156. Koch E. Inhibition of platelet activating factor (PAF)-induced aggregation of human thrombocytes by ginkgolides: considerations on possible bleeding complications after oral intake of Ginkgo biloba extracts. Phytomedicine 2005; 12: 10-6
157. Guinot P, Caffrey E, Lambe R, et al. Tanakan inhibits platelet-activating-factor-induced platelet aggregation in healthy male volunteers. Haemostasis 1989; 19: 219-23
158. Jung F, Mrowietz C, Kiesewetter H, et al. Effect of Ginkgo biloba on fluidity of blood and peripheral microcirculation in volunteers. Arzneimittelforschung 1990; 40: 589-93
159. Bal Dit Sollier C, Caplain H, Drouet L. No alteration in platelet function or coagulation induced by EGb761 in a controlled study. Clin Lab Haematol 2003; 25: 251-3
160. Mehlsen J, Drabaek H, Wiinberg N, et al. Effects of a Ginkgo biloba extract on forearm haemodynamics in healthy volunteers. Clin Physiol Funct Imaging 2002; 22: 375-8
161. Nilsson OG, Lindgren A, Stahl N, et al. Incidence of intracerebral and subarachnoid haemorrhage in southern Sweden. J Neurol Neurosurg Psychiatry 2000; 69: 601-7
162. Jezova D, Duncko R, Lassanova M, et al. Reduction of rise in blood pressure and cortisol release during stress by Ginkgo biloba extract (EGb 761) in healthy volunteers. J Physiol Pharmacol 2002; 53: 337-48
163. Lagrue G, Behar A, Kazandjian M, et al. Idiopathic cyclic edema: the role of capillary hyperpermeability and its correction by Ginkgo biloba extract [in French]. Presse Med 1986; 15: 1550-3
164. Sasaki K, Hatta S, Haga M, et al. Effects of bilobalide on gamma-aminobutyric acid levels and glutamic acid decarboxylase in mouse brain. Eur J Pharmacol 1999; 367: 165-73
165. Schubert H, Halama P. Primär therapieresistente depressive Verstimmung älterer Patienten mit Hirnleistungsstörrungen: Wirksamkeit der Kombination von Ginkgo-biloba-Extrakt EGb 761 mit Antidepressiva. Geriat Forsch 1993; 3: 45-53
166. Cohen AJ, Bartlik B. Ginkgo biloba for antidepressant-induced sexual dysfunction. J Sex Marital Ther 1998; 24: 139-43
167. Wheatley D. Ginkgo biloba relieves sexual dysfunction due to antidepressant drugs. Eur Neuropsychopharmacol 1999; 9: S253-4
168. Ashton AK, Ahrens K, Gupta S, et al. Antidepressant-induced sexual dysfunction and Ginkgo biloba. Am J Psychiatry 2000; 157: 836-7
169. Kang BJ, Lee SJ, Kim MD, et al. A placebo-controlled, double-blind trial of Ginkgo biloba for antidepressant-induced sexual dysfunction. Hum Psychopharmacol 2002; 17: 279-84
170. Zhang XY, Zhou DF, Zhang PY, et al. A double-blind, placebo-controlled trial of extract of Ginkgo biloba added to haloperidol in treatment-resistant patients with schizophrenia. J Clin Psychiatry 2001; 62: 878-83
171. Gregory PJ. Seizure associated with Ginkgo biloba? [letter]. Ann Intern Med 2001; 134: 344
172. Kajiyama Y, Fujii K, Takeuchi H, et al. Ginkgo seed poisoning. Pediatrics 2002; 109: 325-7
173. Miwa H, Iijima M, Tanaka S, et al. Generalized convulsions after consuming a large amount of gingko nuts. Epilepsia 2001; 42: 280-1
174. Arenz A, Klein M, Fiehe K, et al. Occurrence of neurotoxic 4′-0-methylpyridoxin in Ginkgo biloba leaves, medications and Japanese ginkgo food. Planta Med 1996; 62: 548-51
175. Wada K, Ishigaki S, Ueda K, et al. An antivitamin B6, 4′-methoxypyridoxine, from the seed of Ginkgo biloba L. Chem Pharm Bull (Tokyo) 1985; 33: 3555-7
176. Manocha A, Pillai KK, Husain SZ. Effect of Ginkgo biloba on chemoshock in mice. Ind J Pharmacol 1997; 29: 198-200
177. Manocha A, Pillai KK, Husain SZ. Influence of Ginkgo biloba on the effect of anticonvulsants. Indian J Pharmacol 1996; 28: 84-7
178. Gaudineau C, Beckerman R, Welbourn S, et al. Inhibition of human P450 enzymes by multiple constituents of the Ginkgo biloba extract. Biochem Biophys Res Commun 2004; 318: 1072-8
179. von Moltke LL, Weemhoff JL, Bedir E, et al. Inhibition of human cytochromes P450 by components of Ginkgo biloba. J Pharm Pharmacol 2004; 56: 1039-44
180. Mahady GB, Chadwick LR. Goldenseal (Hydrastis canadensis): is there enough scientific evidence to support safety and efficacy? Nutr Clin Care 2001; 4: 243-9
181. Edwards DJ, Draper EJ. Variations in alkaloid content of herbal products containing goldenseal. J Am Pharm Assoc 2003; 43: 419-23
182. Foster BC, Vandenhoek S, Hana J, et al. In vitro inhibition of human cytochrome P450-mediated metabolism of marker substrates by natural products. Phytomedicine 2003; 10: 334-42
183. Chatterjee P, Franklin MR. Human cytochrome P450 inhibition and metabolic-intermediate complex formation by goldenseal extract and its methylenedioxyphenyl components. Drug Metab Dispos 2003; 31: 1391-7
184. Lin HL, Liu TY, Lui WY, et al. Up-regulation of multidrug resistance transporter expression by berberine in human and murine hepatoma cells. Cancer 1999; 85: 1937-42
185. Maeng HJ, Yoo HJ, Kim IW, et al. P-glycoprotein-mediated transport of berberine across Caco-2 cell monolayers. J Pharm Sci 2002; 91: 2614-21
186. Rigelsky JM, Sweet BV. Hawthorn: pharmacology and therapeutic uses. Am J Health Syst Pharm 2002; 59: 417-22
187. Vierling W, Brand N, Gaedcke F, et al. Investigation of the pharmaceutical and pharmacological equivalence of different hawthorn extracts. Phytomedicine 2003; 10: 8-16
188. Pittler MH, Schmidt K, Ernst E. Hawthorn extract for treating chronic heart failure: meta-analysis of randomized trials. Am J Med 2003; 114: 665-74
189. Weikl A, Assmus KD, Neukum-Schmidt A, et al. Crataegus special extract WS 1442: assessment of objective effectiveness in patients with heart failure (NYHA II) [in German]. Fortschr Med 1996; 114: 291-6
190. Tauchert M. Efficacy and safety of crataegus extract WS 1442 in comparison with placebo in patients with chronic stable New York Heart Association class-III heart failure. Am Heart J 2002; 143: 910-5
191. Wolkerstorfer H. Treatment of heart disease with a digoxin-crataegus combination [in German]. Munch Med Wochenschr 1966; 108: 438-41
192. Holubarsch CJ, Colucci WS, Meinertz T, et al. Survival and Prognosis: Investigation of Crataegus extract WS 1442 in congestive heart failure (SPICE): rationale, study design and study protocol. Eur J Heart Fail 2000; 2: 431-7
193. Pittler MH, Ernst E. Kava extract for treating anxiety. Cochrane Database Syst Rev 2003; (1): CD003383
194. Mathews JD, Riley MD, Fejo L, et al. Effects of the heavy usage of kava on physical health: summary of a pilot survey in an aboriginal community. Med J Aust 1988; 148: 548-55
195. From the Centers for Disease Control and Prevention. Hepatic toxicity possibly associated with kava-containing products: United States, Germany, and Switzerland, 1999-2002. JAMA 2003; 289: 36-7
196. Bauer R, Kopp B, Nahrstedt A. Relevant hepatotoxic effects of kava still need to be proven: a statement of the society for medicinal plant research. Planta Med 2003; 69: 971-2
197. Anke J, Ramzan I. Kava hepatotoxicity: are we any closer to the truth. Planta Med 2004; 70: 193-6
198. Russmann S, Lauterburg BH, Helbling A. Kava hepatotoxicity. Ann Intern Med 2001; 135: 68-9
199. Clouatre DL. Kava kava: examining new reports of toxicity. Toxicol Lett 2004; 150: 85-96
200. Zou L, Harkey MR, Henderson GL, et al. Kava does not display metabolic toxicity in a homogeneous cellular assay. Planta Med 2004; 70: 289-92
201. Mathews JM, Etheridge AS, Black SR. Inhibition of human cytochrome P450 activities by kava extract and kavalactones. Drug Metab Dispos 2002; 30: 1153-7
202. Unger M, Holzgrabe U, Jacobsen W, et al. Inhibition of cytochrome P450 3A4 by extracts and kavalactones of Piper methysticum (Kava-Kava). Planta Med 2002; 68: 1055-8
203. Raucy JL. Regulation of CYP3A4 expression in human hepatocytes by pharmaceuticals and natural products. Drug Metab Dispos 2003; 31: 533-9
204. Zou L, Henderson GL, Harkey MR, et al. Effects of kava (kava-kava, 'Awa, Yaqona, Piper methysticum) on c-DNA-expressed cytochrome P450 enzymes and human cryopreserved hepatocytes. Phytomedicine 2004; 11: 285-94
205. Cote CS, Kor C, Cohen J, et al. Composition and biological activity of traditional and commercial kava extracts. Biochem Biophys Res Commun 2004; 322: 147-52
206. Spillane PK, Fisher DA, Currie BJ. Neurological manifestations of kava intoxication. Med J Aust 1997; 167: 172-3
207. Dinh LD, Simmen U, Bueter KB, et al. Interaction of various Piper methysticum cultivars with CNS receptors in vitro. Planta Med 2001; 67: 306-11
208. Baum SS, Hill R, Rommelspacher H. Effect of kava extract and individual kavapyrones on neurotransmitter levels in the nucleus accumbens of rats. Prog Neuropsychopharmacol Biol Psychiatry 1998; 22: 1105-20
209. Boerner RJ, Klement S. Attenuation of neuroleptic-induced extrapyramidal side effects by Kava special extract WS 1490. Wien Med Wochenschr 2004; 154: 508-10
210. Friese J, Gleitz J. Kavain, dihydrokavain, and dihydromethysticin non-competitively inhibit the specific binding of [3H]-batrachotoxinin-A 20-alpha-benzoate to receptor site 2 of voltage-gated Na+ channels. Planta Med 1998; 64: 458-9
211. Gleitz J, Friese J, Beile A, et al. Anticonvulsive action of (+/-)-kavain estimated from its properties on stimulated synaptosomes and Na+ channel receptor sites. Eur J Pharmacol 1996; 315: 89-97
212. Jussofie A, Schmiz A, Hiemke C. Kavapyrone enriched extract from Piper methysticum as modulator of the GABA binding site in different regions of rat brain. Psychopharmacology (Berl) 1994; 116: 469-74
213. Woelk H, Kapoula O, Lehrl S, et al. Treatment of anxiety patients. Double-blind study: kava special extract WS 1490 versus benzodiazepine [in German]. Z Allg Med 1993; 69: 271-7
214. Geßner B, Cnota P. Untersuchungen der Vigilanz nach Applikation von Kava-Kava-Extrakt, Diazepam oder Plazebo. Z Phytother 1994; 15: 30-7
215. Davis KM, Wu JY. Role of glutamatergic and GABAergic systems in alcoholism. J Biomed Sci 2001; 8: 7-19
216. Rotblatt MD. Cranberry, feverfew, horse chestnut, and kava. West J Med 1999; 171: 195-8
217. Perez J, Holmes JF. Altered mental status and ataxia secondary to acute Kava ingestion. J Emerg Med 2005; 28: 49-51
218. Jamieson DD, Duffield PH. Positive interaction of ethanol and kava resin in mice. Clin Exp Pharmacol Physiol 1990; 17: 509-14
219. Saller R, Meier R, Brignoli R. The use of silymarin in the treatment of liver diseases. Drugs 2001; 61: 2035-63
220. Wagner H, Diesel P, Seitz M. The chemistry and analysis of silymarin from Silybum marianum Gaertn [in German]. Arzneimittelforschung 1974; 24: 466-71
221. Enjalbert F, Rapior S, Nouguier-Soule J, et al. Treatment of amatoxin poisoning: 20-year retrospective analysis. J Toxicol Clin Toxicol 2002; 40: 715-57
222. Beckmann-Knopp S, Rietbrock S, Weyhenmeyer R, et al. Inhibitory effects of silibinin on cytochrome P-450 enzymes in human liver microsomes. Pharmacol Toxicol 2000; 86: 250-6
223. Venkataramanan R, Ramachandran V, Komoroski BJ, et al. Milk thistle, a herbal supplement, decreases the activity of CYP3A4 and uridine diphosphoglucuronosyl transferase in human hepatocyte cultures. Drug Metab Dispos 2000; 28: 1270-3
224. Zuber R, Modriansky M, Dvorak Z, et al. Effect of silybin and its congeners on human liver microsomal cytochrome P450 activities. Phytother Res 2002; 16: 632-8
225. Zhang S, Morris ME. Effect of the flavonoids biochanin A and silymarin on the P-glycoprotein-mediated transport of digoxin and vinblastine in human intestinal Caco-2 cells. Pharm Res 2003; 20: 1184-91
226. Jordt SE, McKemy DD, Julius D. Lessons from peppers and peppermint: the molecular logic of thermosensation. Curr Opin Neurobiol 2003; 13: 487-92
227. Hawthorn M, Ferrante J, Luchowski E, et al. The actions of peppermint oil and menthol on calcium channel dependent processes in intestinal, neuronal and cardiac preparations. Aliment Pharmacol Ther 1988; 2: 101-18
228. Hills JM, Aaronson PI. The mechanism of action of peppermint oil on gastrointestinal smooth muscle: an analysis using patch clamp electrophysiology and isolated tissue pharmacology in rabbit and guinea pig. Gastroenterology 1991; 101: 55-65
229. Eccles R. Menthol: effects on nasal sensation of airflow and the drive to breathe. Curr Allergy Asthma Rep 2003; 3: 210-4
230. Gobel H, Fresenius J, Heinze A, et al. Effectiveness of Oleum menthae piperitae and paracetamol in therapy of headache of the tension type [in German]. Nervenarzt 1996; 67: 672-81
231. Javorka K, Tomori Z, Zavarska L. Protective and defensive airway reflexes in premature infants. Physiol Bohemoslov 1980; 29: 29-35
232. Wyllie JP, Alexander FW. Nasal instillation of 'Olbas Oil' in an infant. Arch Dis Child 1994; 70: 357-8
233. Pittler MH, Ernst E. Peppermint oil for irritable bowel syndrome: a critical review and metaanalysis. Am J Gastroenterol 1998; 93: 1131-5
234. Dalvi SS, Nadkarni PM, Pardesi R, et al. Effect of peppermint oil on gastric emptying in man: a preliminary study using a radiolabelled solid test meal. Indian J Physiol Pharmacol 1991; 35: 212-4
235. Micklefield GH, Greving I, May B. Effects of peppermint oil and caraway oil on gastroduodenal motility. Phytother Res 2000; 14: 20-3
236. Goerg KJ, Spilker T. Effect of peppermint oil and caraway oil on gastrointestinal motility in healthy volunteers: a pharmacodynamic study using simultaneous determination of gastric and gall-bladder emptying and orocaecal transit time. Aliment Pharmacol Ther 2003; 17: 445-51
237. Gelal A, Guven H, Balkan D, et al. Influence of menthol on caffeine disposition and pharmacodynamics in healthy female volunteers. Eur J Clin Pharmacol 2003; 59: 417-22
238. Maliakal PP, Wanwimolruk S. Effect of herbal teas on hepatic drug metabolizing enzymes in rats. J Pharm Pharmacol 2001; 53: 1323-9
239. Wacher VJ, Wong S, Wong HT. Peppermint oil enhances cyclosporine oral bioavailability in rats: comparison with D-alpha-tocopheryl poly(ethylene glycol 1000) succinate (TPGS) and ketoconazole. J Pharm Sci 2002; 91: 77-90
240. Wilt T, Ishani A, MacDonald R. Serenoa repens for benign prostatic hyperplasia. Cochrane Database Syst Rev 2002; (3): CD001423
241. Habib FK, Wyllie MG. Not all brands are created equal: a comparison of selected components of different brands of Serenoa repens extract. Prostate Cancer Prostatic Dis 2004; 7: 195-200
242. Buck AC. Is there a scientific basis for the therapeutic effects of serenoa repens in benign prostatic hyperplasia? Mechanisms of action. J Urol 2004; 172: 1792-9
243. Cheema P, El-Mefty O, Jazieh AR. Intraoperative haemorrhage associated with the use of extract of saw palmetto herb: a case report and review of literature. J Intern Med 2001; 250: 167-9
244. Houghton PJ. The scientific basis for the reputed activity of valerian. J Pharm Pharmacol 1999; 51: 505-12
245. Bounthanh C, Bergmann C, Beck JP, et al. Valepotriates, a new class of cytotoxic and antitumor agents. Planta Med 1981; 41: 21-8
246. Bos R, Hendriks H, Scheffer JJC, et al. Cytotoxic potential of valerian constituents and valerian tinctures. Phytomedicine 1998; 5: 219-25
247. Shohet D, Wills RBH, Stuart DL. Valepotriates and valerenic acids in commercial preparations of valerian available in Australia. Pharmazie 2001; 56: 860-3
248. MacGregor FB, Abernethy VE, Dahabra S, et al. Hepatotoxicity of herbal remedies. BMJ 1989; 299: 1156-7
249. Chan TY, Tang CH, Critchley JA. Poisoning due to an over-the-counter hypnotic, Sleep-Qik (hyoscine, cyproheptadine, valerian). Postgrad Med J 1995; 71: 227-8
250. Chan TY. An assessment of the delayed effects associated with valerian overdose. Int J Clin Pharmacol Ther 1998; 36: 569
251. Riedel E, Hansel R, Ehrke G. Inhibition of gamma-aminobutyric acid catabolism by valerenic acid derivatives [in German]. Planta Med 1982; 46: 219-20
252. Ortiz JG, Nieves-Natal J, Chavez P. Effects of Valeriana officinalis extracts on [3H]flunitrazepam binding, synaptosomal [3H]GABA uptake, and hippocampal [3H]GABA release. Neurochem Res 1999; 24: 1373-8
253. Donath F, Quispe S, Diefenbach K, et al. Critical evaluation of the effect of valerian extract on sleep structure and sleep quality. Pharmacopsychiatry 2000; 33: 47-53
254. Dorn M. Efficacy and tolerability of Baldrian versus oxazepam in non-organic and non-psychiatric insomniacs: a randomised, double-blind, clinical, comparative study [in German]. Forsch Komplementarmed Klass Naturheilkd 2000; 7: 79-84
255. Garges HP, Varia I, Doraiswamy PM. Cardiac complications and delirium associated with valerian root withdrawal. JAMA 1998; 280: 1566-7
256. Lindenmayer JP. The pathophysiology of agitation. J Clin Psychiatry 2000; 61: 5-10
257. van der Mast RC, Fekkes D. Serotonin and amino acids: partners in delirium pathophysiology? Semin Clin Neuropsychiatry 2000; 5: 125-31
258. Schwartz RH, Rodriquez WJ. Toxic delirium possibly caused by loperamide. J Pediatr 1991; 118: 656-7
259. Chang PH, Steinberg MB. Alcohol withdrawal. Med Clin North Am 2001; 85: 1191-212
260. Leuschner J, Muller J, Rudmann M. Characterisation of the central nervous depressant activity of a commercially available valerian root extract. Arzneimittelforschung 1993; 43: 638-41
261. Waked M, Bismuth C, Capron F, et al. Lipid pneumonia discovered in a case of epiphenomenal drug poisoning [in French]. Presse Med 1991; 20: 178
262. Willey LB, Mady SP, Cobaugh DJ, et al. Valerian overdose: a case report. Vet Hum Toxicol 1995; 37: 364-5
263. Wells SR. Intentional intravenous administration of a crude valerian root extract [abstract]. J Toxicol Clin Toxicol 1995; 33: 542
264. Mullins ME, Horowitz BZ. The case of the salad shooters: intravenous injection of wild lettuce extract. Vet Hum Toxicol 1998; 40: 290-1
265. Barnes J, Mills SY, Abbot NC, et al. Different standards for reporting ADRs to herbal remedies and conventional OTC medicines: face-to-face interviews with 515 users of herbal remedies. Br J Clin Pharmacol 1998; 45: 496-500
266. Ernst E. Challenges for phytopharmacovigilance. Postgrad Med J 2004; 80: 249-50
267. Butterweck V, Derendorf H, Gaus W, et al. Pharmacokinetic herb-drug interactions: are preventive screenings necessary and appropriate? Planta Med 2004; 70: 784-91